Cardiovascular Applications of Fluorocarbons: Current Status and Future Direction -A Critical Clinical Appraisal

References

• Tennant R., Wiggers C. J. The effect of coronary occlusion on myocardial contractions. Am Physiol J 1935; 112: 351
   Google Scholar
• Reimer K. A., Lowe J. E., Rasmussen M. M., Jennings R. B. The wavefront phenomenon of ischemic cell death. I. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation 1977; 56: 786
   PubMed Web of Science ®Google Scholar
• Roberts C. S., Anderson H. V., Carboni A. A., Justicz A. G.S., Leimgruber P. P., Kloner R. A., Gruentzig A. R. Usefulness of intracoronary infusion of fluorocarbon distal to prolonged coronary occlusion by angioplasty balloon in dogs. Am J Cardiol 1986; 57: 1202–1205
   PubMed Web of Science ®Google Scholar
• Flaherty J. T., Jaffin J. H., Magovern G. J., Jr., Kanter K. R., Gardner T. J., Miceli M. V., Jacobus W. E. Maintenance of aerobic metabolism during global ischemia with perfluorocarbon cardioplegia improves myocardial preservation. Circulation 1984; 69: 585–592
   PubMed Web of Science ®Google Scholar
• Bajaj A. K., Cobb M. A., Virmani R., Gay J. C., Light R. T., Forman M. B. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals: Role of Neutrophil Activation. Circulation 1989; 79: 645–656
   PubMed Web of Science ®Google Scholar
• Forman M. B., Perry J. M., Wilson B. H., Verani M. S., Kaplan P. R., Shawl F. A., Friesinger G. C. Demonstration of myocardial reperfusion injury in humans: Results of a pilot study utilizing acute coronary angioplasty with perfluorochemical in anterior myocardial infarction. J Am Coll Cardiol 1991; 18: 911–918
   PubMed Web of Science ®Google Scholar
• Cleman M., Jaffee C. C., Wohlgelernter D. Prevention of ischemia during percutaneous transluminal coronary angioplasty by transcatheter infusion of oxygenated Fluosol DA 20%. Circulation 1986; 74(3)555–562
   PubMed Web of Science ®Google Scholar
• Faxon D. P., Weber V. J., Haudenschild C. C., Gottsman S. B., McGovern W. A., Ryan T. J. Acute effects of transluminal angioplasty in three experimental models of atherosclerosis. Atherosclerosis 1982; 2: 125–133
   Google Scholar
• Hirshfeld J. W., Schwartz J. S., Jugo R, MacDonald R. G., Goldberg S., Savage M. P., Bass T. A., Vetrovec G., Cowley M., Taussig AS., Whitworth H. B., Margolis J. R., Hill J. A., Pepine C. J., The M-Heart Investigators. Restenosis after coronary angioplasty: A multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol 1991; 18: 647–656
   PubMed Web of Science ®Google Scholar
• Tokioka H., Miyazaki A., Fung P., Rajagopalan R. E., Kar S., Meerbaum S., Corday E., Drury J. K. Effects of intracoronary infusion of arterial blood or Fluosol-DA 20% on regional myocardial metabolism and function during brief coronary artery occlusions. Circulation 1987; 75(2)473–481
   PubMedGoogle Scholar
• Young L. H., Jaffe C. C., Revkin J. H., McNulty P. H., Cleman M. Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplasty. Am J Cardiol 1990; 65: 986–990
   PubMed Web of Science ®Google Scholar
• Kent K. M., Cleman M. W., Cowley M. J., Forman M. B., Jaffe C. C., Kaplan M., King S. B., III, Krucoff M. W., Lassar T., McAuley B., Smith R., Wisdom C., Wohlgelernter D. Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol. Am J Cardiol 1990; 66: 279–284
   PubMed Web of Science ®Google Scholar
• Riess J. G., Dalfors J. L., Hanna G. K., Klein D. H., Krafft M.-P., Pelura T. J., Schutt E. G. Development of highly fluid, concentrated and stable fluorocarbon emulsions for diagnosis and therapy. Biomat, Art. Cells and Immob Biotech 1992; 20: 839–842
   PubMed Web of Science ®Google Scholar
• Riess J. G. Overview on progress in the fluorocarbon approach to in vivo oxygen delivery. Blood Substitutes and Oxygen Carriers, T. M.S. Chang. Marcel Dekker, Inc., New York 1993; 24–43
   Google Scholar
• Ogilby J. D., Noma S., DiLoretto G., Stets G. Preservation of myocardial function during ischemia with intracoronary perfluoroocytlbromide (Oxygent™). Blood Substitutes and Oxygen Carriers, T. M.S. Chang. Marcel Dekker, Inc., New York 1993; 728–732
   Google Scholar
• Christensen C. W., Reeves W. C., Lassar T. A., Schmidt D. H. Inadequate subendocardial oxygen delivery during perfluorocarbon perfusion in a canine model of ischemia. Am Heart J 1988; 115: 30–37
   PubMed Web of Science ®Google Scholar
• Quigley P. J., Hinohara T., Phillips H. R., Peter R. H., Behar V. S., Kong Y., Simonton C. A., Perez J. A., Stack R. S. Myocardial protection during coronary angioplasty with an autoperfusion balloon catheter in humans. Circulation 1988; 78: 1128–1134
   PubMedGoogle Scholar
• Smith J. E., Quigley P. J., Tcheng J. E., Bauman R. P., Thomas J., Stack R. S. Can prolonged perfusion balloon inflations salvage vessel patency after failed angioplasty. Circulation 1989; 80: II–373, (Suppl II)
   Google Scholar
• Cowley M. J., Snow F. R., DiSciascio G., Kelly K., Guard C., Nixon J. V. Perfluorochemical perfusion during coronary angioplasty in unstable and high-risk patients. Circulation 1990; 81: IV27–IV34, (suppl IV)
   PubMedGoogle Scholar
• Kennedy J., Ritchie J., Davis K., Fritz J. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983; 309: 1477–1482
   PubMed Web of Science ®Google Scholar
• Gruppo Italiana Per Lo Studio Delia Streptokinase Nell Infarcto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–401
   PubMedGoogle Scholar
• Hearse D. J. Reperfusion of the ischemic myocardium. J Mol and Cell Cardiol 1977; 9: 605–616
   PubMed Web of Science ®Google Scholar
• Engler R. L., Schmid-Schoenbein G. W., Pavelec R. S. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 1983; 111: 98–111
   PubMed Web of Science ®Google Scholar
• Engler R. L., Dahlgren M. D., Morris D. D., Peterson M. A., Schmidt-Schoenbein G. W. Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. Am J Physiol 1986; 251: H314–H322
   PubMed Web of Science ®Google Scholar
• Braunwald E., Kloner R. A. Myocardial reperfusion: A double-edged sword. J Clin Invest 1985; 76: 1713–1719
   PubMed Web of Science ®Google Scholar
• Follette D. M., Fey K., Buckberg G. D., Helly J. J., Steed D. L., Foglia R. P., Mahoney J. V. Reducing postischemic damage by temporary modification of reperfusate calcium, potassium, pH, and osmolarity. J Thorac Cardiovasc Surg 1981; 82: 221–238
   PubMed Web of Science ®Google Scholar
• Acar C., Partington M. T., Buckberg G. D. Studies of controlled reperfusion after ischemia: XIX. Reperfusate composition: Benefits of blood cardioplegia over Fluosol DA cardioplegia during regional reperfusion - Importance of including blood components in the initial reperfusate. J Thorac Cardiovasc Surg 1991; 101: 284–293
   PubMedGoogle Scholar
• Martin S. M., Laks H., Drinkwater D. C., Stein D. G., Barthel S. W., Capouya E. R., Pearl J. M., Bhuta S., Ho B., Chang P. Perfluorochemical reperfusion limits myocardial reperfusion injury after prolonged hypothermic global ischemia. Blood Substitutes and Oxygen Carriers, T. M.S. Chang. Marcel Dekker, Inc., New York 1993; 738–742
   Google Scholar
• Pearl J. M., Laks H., Drinkwater D. C., Meneshian A., Martin S. M., Curzan M., Chang P. A. Fluosol cardioplegia results in complete functional recovery: A comparison with blood cardioplegia. Ann Thorac Surg 1992; 54: 1144–50
   PubMedGoogle Scholar
• Rice H. E., Virmani R., Hart C. L., Kolodgie F. D., Farb A. Dose-dependent reduction of myocardial infarct size with the perfluorochemical Fluosol-DA. Am Heart J 1990; 120: 1039–1046
   PubMed Web of Science ®Google Scholar
• Litt M. R., Jeremy R. W., Weisman H. F., Winkelstein J. A., Becker L. C. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia: Evidence for neutrophil-mediated reperfusion injury. Circulation 1989; 80: 1816–1827
   PubMed Web of Science ®Google Scholar
• Vitola J. V., Rigsby T. W., Ingram D. A., Atkinson J. B., Murray J. J., Forman M. B. The beneficial effect of Fluosol™ to reduce myocardial reperfusion injury is independent of its oxygen carrying ability. J Am Coll Cardiol 1993; 21: 399A
   Google Scholar
• Schaer G. L., Hursey T. L., Rodriguez E. R., Campbell D. R., Song J. K., Manabat N. C., Thota V., Parrillo J. E. Poloxamer 188, a Component of perfluorochemical emulsion (Fluosol™), reduces myocardial infarct size in dogs. Circulation 1991; 84: II–619, (Suppl II)
   Google Scholar
• Forman M. B., Pitarys C. J., Vildibill H. D., Lambert T. L., Ingram D. A., Virmani R., Murray J. J. Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion. J Am Coll Cardiol 1992; 19: 205–216
   PubMed Web of Science ®Google Scholar
• Wall T. C., Topol E. J., Califf R. M., Blankenship J., Talley D., Tannenbaum M., Gacioch G., Cohen M., Sanz M., Leimberger J., For the TAMI 9 Study Group. TAMI 9: Preliminary report of a prospective randomized trial of intravenous Fluosol in acute myocardial infarction. Circulation 1992; 86: I–642, (Suppl I)
   Google Scholar